AngioDynamics Reports Fiscal 2023 Second Quarter; Reaffirms Guidance

 Fiscal Year 2023 Second Quarter Highlights

• Net sales of $85.4 million increased 9.1% compared to the prior-year quarter
  • Med Tech net sales of $24.5 million increased 29.7%
  • Med Device net sales of $60.9 million increased 2.6%
• Gross margin of 52.8% increased 100 basis points year over year
• GAAP loss per share of $0.21 and adjusted earnings per share of $0.01

Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth.

Conference Call

The Company's management will host a conference call today at 8:00 a.m. ET to discuss its second quarter results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13734978.

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Thursday, January 5, 2023, until 11:59 p.m. ET on Thursday, January 12, 2023. To listen to this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13734978.

https://www.biospace.com/article/releases/angiodynamics-reports-fiscal-2023-second-quarter-financial-results-reaffirms-guidance/